Prophylaxis of heterotopic ossification-an updated review

Journal of Orthopaedic Surgery and Research

Volumn 4, Issue 1, 2009, Pages

  Baird, Evan O ^b   Kang, Qian K ^a,b  

^a CLEMSON UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 65449174836     PISSN: None     EISSN: 1749799X     Source Type: Journal    
DOI: 10.1186/1749-799X-4-12     Document Type: Article

References (72)

1. Heterotopic ossification: a review. L Vanden Bossche G Vanderstraeten, J Rehabil Med 2005 37 129 136 10.1080/16501970510027628 16040468 (Pubitemid 40775150)
2. Retroviral delivery of Noggin inhibits the formation of heterotopic ossification induced by BMP-4, demineralized bone matrix, and trauma in an animal model. D Hannallah H Peng B Young A Usas B Gearhart J Huard, J Bone Joint Surg Am 2004 86-A 80 91 14711949 (Pubitemid 38057340)
3. The role of radiotherapy for prevention of heterotopic ossification after major hip surgery. FJ Andreu Martinez JM Martinez Mateu V Tormo Ferrero, Clin Transl Oncol 2007 9 28 31 10.1007/s12094-007-0006-7 17272227
4. Heterotopic ossification: Pathophysiology, clinical features, and the role of radiotherapy for prophylaxis. TA Balboni R Gobezie HJ Mamon, Int J Radiat Oncol Biol Phys 2006 65 1289 1299 16863921 (Pubitemid 44425235)
5. The prophylaxis and treatment of heterotopic ossification following lower limb arthroplasty. TN Board A Karva RE Board AK Gambhir ML Porter, J Bone Joint Surg Br 2007 89 434 440 10.1302/0301-620X.89B4.18845 17463108 (Pubitemid 46851120)
6. Intramedullary nailing of tibial nonunions. SB Warren AF Brooker Jr, Clin Orthop 1992 236 243 1446444
7. Heterotopic ossification. D Shehab AH Elgazzar BD Collier, J Nucl Med 2002 43 346 353 11884494 (Pubitemid 34208096)
8. Radiation therapy for heterotopic ossification. TC Lo, Semin Radiat Oncol 1999 9 163 170 10.1016/S1053-4296(99)80006-X 10092708 (Pubitemid 29187969)
9. Prevention of heterotopic ossification in high-risk patients with total hip arthroplasty: the experience of a combined therapeutic protocol. EE Pakos EJ Pitouli PG Tsekeris V Papathanasopoulou K Stafilas TH Xenakis, Int Orthop 2006 30 79 83 16482442 10.1007/s00264-005-0054-y
10. The mechanisms of the inhibitory effects of nonsteroidal anti-inflammatory drugs on bone healing: a concise review. AT Harder YH An, J Clin Pharmacol 2003 43 807 815 10.1177/0091270003256061 12953337 (Pubitemid 36886100)
11. Determinants of pathological mineralization. T Kirsch, Curr Opin Rheumatol 2006 18 174 180 10.1097/01.bor.0000209431.59226.46 16462525 (Pubitemid 43740392)
12. Early changes in prostaglandins precede bone formation in a rabbit model of heterotopic ossification. CS Bartlett BE Rapuano DG Lorich T Wu RC Anderson E Tomin JF Hsu JM Lane DL Helfet, Bone 2006 38 322 332 10.1016/j.bone.2005.08.016 16226065 (Pubitemid 43255426)
13. Heterotopic bone formation: presentation of an experimental rat model and a clinical case. HH Cohly RC Buckley R Pecunia SK Das, Biomed Sci Instrum 2003 39 446 453 12724934 (Pubitemid 36433467)
14. Myositis ossificans following forcible manipulation of the leg. A rabbit model for the study of heterotopic bone formation. JE Michelsson G Granroth LC Andersson, J Bone Joint Surg Am 1980 62 811 815 7391105 (Pubitemid 10003655)
15. Animal models of heterotopic ossification. JP O'Connor, Clin Orthop Relat Res 1998 71 80 9577413 (Pubitemid 28046870)
16. The origin of osteoprogenitor cells responsible for heterotopic ossification following hip surgery: an animal model in the rabbit. MN Rumi GS Deol KP Singapuri VD Pellegrini Jr, J Orthop Res 2005 23 34 40 10.1016/j.orthres.2004.05.003 15607872 (Pubitemid 40045074)
17. The Frank Stinchfield Award. Inhibition of heterotopic ossification with radiation therapy in an animal model. DJ Schneider MJ Moulton K Singapuri V Chinchilli GS Deol G Krenitsky VD Pellegrini Jr, Clin Orthop Relat Res 1998 35 46 10.1097/00003086-199810000-00005 9917589
18. Changes in bone formation during immobilization and development of experimental osteoarthritis. JE Michelsson T Videman A Langenskiold, Acta Orthop Scand 1977 48 443 449 596139
19. The efficiency of muscle-derived cell-mediated bone formation. P Bosch D Musgrave S Ghivizzani C Latterman CS Day J Huard, Cell Transplant 2000 9 463 470 11038063
20. Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. JR Lieberman LQ Le L Wu GA Finerman A Berk ON Witte S Stevenson, J Orthop Res 1998 16 330 339 10.1002/jor.1100160309 9671928 (Pubitemid 28337629)
21. Effect of bone morphogenetic protein-2-expressing muscle-derived cells on healing of critical-sized bone defects in mice. JY Lee D Musgrave D Pelinkovic K Fukushima J Cummins A Usas P Robbins FH Fu J Huard, J Bone Joint Surg Am 2001 83-A 1032 1039 11451972 (Pubitemid 32662105)
22. Bone: formation by autoinduction. MR Urist, Science 1965 150 893 899 10.1126/science.150.3698.893 5319761
23. Bone morphogenetic protein-2: biology and applications. EH Riley JM Lane MR Urist KM Lyons JR Lieberman, Clin Orthop Relat Res 1996 39 46 10.1097/00003086-199603000-00006 8595775 (Pubitemid 26071749)
24. Prevention of heterotopic ossification after spinal cord injury with indomethacin. K Banovac JM Williams LD Patrick YM Haniff, Spinal Cord 2001 39 370 374 10.1038/sj.sc.3101166 11464310 (Pubitemid 32758622)
25. Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone nonunion. TA Burd MS Hughes JO Anglen, J Bone Joint Surg Br 2003 85 700 705 12892193 (Pubitemid 36927035)
26. Indometacin as prophylaxis for heterotopic ossification after the operative treatment of fractures of the acetabulum. MA Karunakar A Sen MJ Bosse SH Sims JA Goulet JF Kellam, J Bone Joint Surg Br 2006 88 1613 1617 10.1302/0301-620X.88B12.18151 17159174
27. A systematic survey of 13 randomized trials of non-steroidal anti-inflammatory drugs for the prevention of heterotopic bone formation after major hip surgery. BC Neal A Rodgers T Clark H Gray IR Reid L Dunn SW MacMahon, Acta Orthop Scand 2000 71 122 128 10.1080/000164700317413076 10852316 (Pubitemid 30611735)
28. Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty. M Fransen B Neal, Cochrane Database Syst Rev 2004 CD001160 15266441
29. COX 2 selectivity of non-steroidal anti-inflammatory drugs and perioperative blood loss in hip surgery. A randomized comparison of indomethacin and meloxicam. EW Weber R Slappendel ME Durieux R Dirksen H van der Heide M Spruit, Eur J Anaesthesiol 2003 20 963 966 10.1097/00003643-200312000-00005 14690098 (Pubitemid 37500224)
30. Safety and efficacy of routine postoperative ibuprofen for pain and disability related to ectopic bone formation after hip replacement surgery (HIPAID): randomised controlled trial. M Fransen C Anderson J Douglas S MacMahon B Neal R Norton M Woodward ID Cameron R Crawford SK Lo, Bmj 2006 333 519 16885182 10.1136/bmj.38925.471146.4F (Pubitemid 44408459)
31. Prophylaxis of heterotopic ossification after total hip arthroplasty: a prospective randomized study comparing indomethacin and meloxicam. T Barthel B Baumann U Noth J Eulert, Acta Orthop Scand 2002 73 611 614 10.1080/ 000164702321039543 12553505 (Pubitemid 36020901)
32. Selective COX-2 inhibitor versus indomethacin for the prevention of heterotopic ossification after hip replacement: a double-blind randomized trial of 100 patients with 1-year follow-up. JG Grohs M Schmidt A Wanivenhaus, Acta Orthop 2007 78 95 98 10.1080/17453670610013484 17453399 (Pubitemid 46570264)
33. COX-2: separating myth from reality. F McKenna, Scand J Rheumatol Suppl 1999 109 19 29 10.1080/030097499750042399 10422543 (Pubitemid 29306629)
34. Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: a prospective randomised trial. M Saudan P Saudan T Perneger N Riand A Keller P Hoffmeyer, J Bone Joint Surg Br 2007 89 155 159 17322426 (Pubitemid 46421457)
35. Prophylaxis for heterotopic ossification after primary total hip arthroplasty. A cohort study between indomethacin and meloxicam. HJ van der Heide M Spruit R Slappendel N Klooster J van Limbeek, Acta Orthop Belg 2004 70 240 246 15287403 (Pubitemid 38879717)
36. Indomethacin versus meloxicam for prevention of heterotopic ossification after total hip arthroplasty. R Legenstein P Bosch A Ungersbock, Arch Orthop Trauma Surg 2003 123 91 94 12664317 (Pubitemid 36748529)
37. Similar effects of rofecoxib and indomethacin on the incidence of heterotopic ossification after hip arthroplasty. HJ van der Heide WJ Rijnberg A Van Sorge A Van Kampen BW Schreurs, Acta Orthop 2007 78 90 94 10.1080/17453670610013475 17453398 (Pubitemid 46570263)
38. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. RS Bresalier RS Sandler H Quan JA Bolognese B Oxenius K Horgan C Lines R Riddell D Morton A Lanas, N Engl J Med 2005 352 1092 1102 10.1056/NEJMoa050493 15713943 (Pubitemid 40365350)
39. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. NA Nussmeier AA Whelton MT Brown RM Langford A Hoeft JL Parlow SW Boyce KM Verburg, N Engl J Med 2005 352 1081 1091 10.1056/NEJMoa050330 15713945 (Pubitemid 40365349)
40. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. SD Solomon JJ McMurray MA Pfeffer J Wittes R Fowler P Finn WF Anderson A Zauber E Hawk M Bertagnolli, N Engl J Med 2005 352 1071 1080 10.1056/NEJMoa050405 15713944 (Pubitemid 40365348)
41. Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. LC Chen DM Ashcroft, J Clin Pharm Ther 2006 31 565 576 10.1111/j.1365-2710.2006.00774.x 17176361
42. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non steroidal anti-inflammatory drugs. MW Van der Linden S Van der Bij P Welsing EJ Kuipers RM Herings, Ann Rheum Dis 2008 68 5 668 673 10.1136/ard.2007.087254 18495734
43. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. E Rahme H Nedjar, Rheumatology (Oxford) 2007 46 435 438 10.1093/rheumatology/kel428 17255138 (Pubitemid 46344654)
44. Pharmacological treatment of heterotopic ossification following hip and acetabular surgery. RJ Macfarlane BH Ng Z Gamie MA El Masry S Velonis C Schizas E Tsiridis, Expert Opin Pharmacother 2008 9 767 786 10.1517/14656566.9.5.767 18345954
45. Effects of nonsteroidal anti-inflammatory drugs on bone formation and soft-tissue healing. LE Dahners BH Mullis, J Am Acad Orthop Surg 2004 12 139 143 15161166
46. Do non-steroidal anti-inflammatory drugs cause endoprosthetic loosening? A 10-year follow-up of a randomized trial on ibuprofen for prevention of heterotopic ossification after hip arthroplasty. PE Persson OS Nilsson AM Berggren, Acta Orthop 2005 76 735 740 10.1080/17453670510045309 16470423
47. The effects of transplantation and x-irradiation on the repair of fractured bones. LM Cooley RJ Goss, Am J Anat 1958 102 167 181 10.1002/aja.1001020202 13571154
48. Osteogenesis by radioisotope labelled cell populations in implants of bone matrix under the influence of ionizing radiation. PL Craven MR Urist, Clin Orthop Relat Res 1971 76 231 243 10.1097/00003086-197105000-00030 4931060
49. The use of radiation to discourage ectopic bone. A nine-year study in surgery about the hip. MB Coventry PW Scanlon, J Bone Joint Surg Am 1981 63 201 208 6780568 (Pubitemid 11154531)
50. Preoperative irradiation for prevention of heterotopic ossification following total hip arthroplasty. VD Pellegrini Jr SJ Gregoritch, J Bone Joint Surg Am 1996 78 870 881 8666605 (Pubitemid 26241990)
51. A prospective evaluation of the timing of postoperative radiotherapy for preventing heterotopic ossification following traumatic acetabular fractures. HA Childs 3rd T Cole E Falkenberg JT Smith JE Alonso JP Stannard SA Spencer J Fiveash D Raben JA Bonner, Int J Radiat Oncol Biol Phys 2000 47 1347 1352 10889389 (Pubitemid 30421188)
52. External beam radiation helps prevent heterotopic bone formation in patients with a history of heterotopic ossification. ST Chao SY Lee LS Borden MJ Joyce VE Krebs JH Suh, J Arthroplasty 2006 21 731 736 10.1016/j.arth.2005.08. 014 16877161 (Pubitemid 44108562)
53. Prevention of heterotopic ossification about the hip: final results of two randomized trials in 410 patients using either preoperative or postoperative radiation therapy. MH Seegenschmiedt L Keilholz P Martus A Goldmann R Wolfel F Henning R Sauer, Int J Radiat Oncol Biol Phys 1997 39 161 171 9300751 (Pubitemid 27396293)
54. Heterotopic bone formation after hip surgery: prevention with single-dose postoperative hip irradiation. TC Lo WL Healy DJ Covall WE Dotter BA Pfeifer WR Torgerson SA Wasilewski, Radiology 1988 168 851 854 3136510 (Pubitemid 18212890)
55. Indomethacin compared with localized irradiation for the prevention of heterotopic ossification following surgical treatment of acetabular fractures. TA Burd KJ Lowry JO Anglen, J Bone Joint Surg Am 2001 83-A 1783 1788 11741055 (Pubitemid 33134431)
56. Prevention of heterotopic bone formation after total hip arthroplasty: a prospective randomised study comparing postoperative radiation therapy with indomethacin medication. H Kienapfel M Koller A Wust C Sprey H Merte R Engenhart-Cabillic P Griss, Arch Orthop Trauma Surg 1999 119 296 302 10.1007/s004020050414 10447627 (Pubitemid 29408402)
57. Indomethacin versus radiation therapy for prophylaxis against heterotopic ossification in acetabular fractures: a randomised, prospective study. KD Moore K Goss JO Anglen, J Bone Joint Surg Br 1998 80 259 263 10.1302/0301-620X.80B2. 8157 9546456 (Pubitemid 28140367)
58. Cost of radiotherapy versus NSAID administration for prevention of heterotopic ossification after total hip arthroplasty. JB Strauss SS Chen AP Shah AB Coon A Dickler, Int J Radiat Oncol Biol Phys 2008 71 1460 1464 18234435
59. Randomized trial comparing early postoperative irradiation vs. the use of nonsteroidal antiinflammatory drugs for prevention of heterotopic ossification following prosthetic total hip replacement. O Kolbl D Knelles T Barthel U Kraus M Flentje J Eulert, Int J Radiat Oncol Biol Phys 1997 39 961 966 9392532 (Pubitemid 27506145)
60. [Value of a combined ossification prophylaxis with indomethacin and radiotherapy for acetabular fractures]. S Piatek T Westphal D Arbter S Winckler, Unfallchirurg 2006 109 556 562 10.1007/s00113-006-1083-8 16786326 (Pubitemid 44090438)
61. HO prevention and the combined therapeutic protocol-do we really need it? KC Kose O Cebesoy L Altinel, Int Orthop 2007 31 133 134 16900355 10.1007/s00264-006-0199-3 (Pubitemid 46208238)
62. The bone morphogenetic proteins antagonist Noggin inhibits membranous ossification. P Aspenberg C Jeppsson AN Economides, J Bone Miner Res 2001 16 497 500 10.1359/jbmr.2001.16.3.497 11277267 (Pubitemid 32173364)
63. A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton. FS Kaplan DL Glaser RJ Pignolo EM Shore, Expert Opin Biol Ther 2007 7 705 712 10.1517/14712598.7.5.705 17477807 (Pubitemid 46710933)
64. [Methods of the physical medicine therapy in prevention of heterotopic ossification after total hip arthroplasty]. M Kocic M Lazovic Z Kojovic M Mitkovic S Milenkovic T Ciric, Vojnosanit Pregl 2006 63 807 811 17039892
65. Characterization of bone morphogenetic protein 4 receptor in fibrodysplasia ossificans progressiva. TF Lanchoney EA Olmsted EM Shore FA Gannon V Rosen MA Zasloff FS Kaplan, Clin Orthop Relat Res 1998 38 45 9577408 (Pubitemid 28046865)
66. Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. L Kan M Hu WA Gomes JA Kessler, Am J Pathol 2004 165 1107 1115 15466378 (Pubitemid 39297718)
67. Paresis of a bone morphogenetic protein-antagonist response in a genetic disorder of heterotopic skeletogenesis. J Ahn L Serrano de la Pena EM Shore FS Kaplan, J Bone Joint Surg Am 2003 85-A 667 674 12672843 (Pubitemid 36538716)
68. In vivo somatic cell gene transfer of an engineered Noggin mutein prevents BMP4-induced heterotopic ossification. DL Glaser AN Economides L Wang X Liu RD Kimble JP Fandl JM Wilson N Stahl FS Kaplan EM Shore, J Bone Joint Surg Am 2003 85-A 2332 2342 14668502 (Pubitemid 37499642)
69. [Could hypoxia of connective tissue lead to heterotopic ossification?]. P Kozlowski, Chir Narzadow Ruchu Ortop Pol 2004 69 241 244 15587379
70. Hypoxic adipocytes pattern early heterotopic bone formation. E Olmsted-Davis FH Gannon M Ozen MM Ittmann Z Gugala JA Hipp KM Moran CM Fouletier-Dilling S Schumara-Martin RW Lindsey, Am J Pathol 2007 170 620 632 17255330 10.2353/ajpath.2007.060692 (Pubitemid 47339399)
71. Effect of exercise training, selenium and vitamin E on some free radical scavengers in horses (Equus caballus). L Avellini E Chiaradia A Gaiti, Comp Biochem Physiol B Biochem Mol Biol 1999 123 147 154 10.1016/S0305-0491(99)00045- 0 10425718 (Pubitemid 29259840)
72. Use of bone morphogenetic protein-9 gene therapy to induce spinal arthrodesis in the rodent. GA Helm TD Alden EJ Beres SB Hudson S Das JA Engh DD Pittman KM Kerns DF Kallmes, J Neurosurg 2000 92 191 196 10763690 (Pubitemid 30207415)